Monday, March 11, 2019 11:41:15 AM
The problem with Oncosec’s current IRES-based plasmid construct and electroporation voltage parameters is that transfection is not optimal, nor is IL-12 expression. If you don’t see adequate IL-12 levels being expressed intratumorally, odds are pretty good that you also won’t observe elevated levels of interferon gamma (and subsequent expression of STAT 1 genes); you won’t observe high T-bet levels, but higher Eomes and more T cell exhaustion; greater Treg ratios; poor tumor antigen presentation; and fewer chemokines that draw T cells into the TME.
I think “Spark”, the new multigene product, will undoubtedly resolve these issues and effectively reduce or completely eliminate the need for anti-PD-1 agents.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM